

**Supplement Table 1.** Clinical characteristics of diabetic patients before and after 6 months of Dapagliflozin treatment

	Baseline (n = 54)	After Dapagliflozin (n = 54)	p-value
Age (years)	61.8±7.7	-	
Male (%)	38 (70.3)	-	
Body height (cm)	164.5±8.2	-	
Body weight (kg)	73.4±11	70.4±10.1	0.35
BMI (kg/M <sup>2</sup> )	27.1±3.3	26±2.9	0.26
Waist (cm)	96.4±8.3	91.5±6.7	<b>0.04</b>
Hypertension	48(88.8)	-	
Systolic blood pressure (mmHg)	131.2±14.2	128±18.7	0.96
Diastolic blood pressure (mmHg)	76.5±8.7	72.4±10.5	0.88
Hyperlipidemia	44(81.4)	-	
Preprandial serum glucose (mg/dl)	157.7±35	123.5±15.5	0.12
HbA1c (%;mmol/mol)	8.1±1.2; 64±10.2	7±0.8; 53±9.8	<b>0.003</b>
eGFR (ml/min)	73.3±24.6	74.8±31.4	0.24
Triglyceride (mg/dL)	160.8±81.6	148.2±92.4	0.12
Cholesterol (mg/dl)	189.1±42.8	171.2±34.6	0.38
LDL	108.9±34.1.	90.9±27.9.	0.51
Medications			
ACEI/ARB, N (%)	41 (76)	-	
B-blocker, N (%)	26 (54.1)	-	
CCB, N (%)	10 (18.5)	-	
Metformin, N (%)	43 (79.6)	-	
TZD, N (%)	3 (5.5)	-	
DDP4, N (%)	27 (50)	-	
Sulfonylureas, N (%)	19 (35.2)	-	
Statins, N (%)	42 (77.7)	-	

Data are expressed as mean ± standard deviation or median (interquartile range). **Bold values** indicate significance. BMI =body mass index; HbA1c = hemoglobin A1c; eGFR= estimated Glomerular filtration rate; LDL= low-density lipoprotein; ACEI/ARB= angiotensin- converting enzyme inhibitors/ angiotensin receptor blockers; CCB= calcium channel blocker; TZD= Thiazolidinedione; DDP4= dipeptidyl peptidase-4 inhibitors